{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:46:21Z","timestamp":1782510381260,"version":"3.54.5"},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ucl.2026.03.006","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:51:54Z","timestamp":1777499514000},"page":"413-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bacillus Calmette-Gu\u00e9rin Therapy"],"prefix":"10.1016","volume":"53","author":[{"given":"Tutku E.","family":"Tazegul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Y.","family":"Hougen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ucl.2026.03.006_bib1","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non\u2013muscle-invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.006_bib2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non\u2013muscle-invasive bladder cancer: AUA\/SUO guideline, 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.006_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.03.006_bib4","unstructured":"Flaig TW, Spiess PE, Abern M, et al. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version published March 25, 2025."},{"issue":"5","key":"10.1016\/j.ucl.2026.03.006_bib5","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.006_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus Calmette-Gu\u00e9rin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol"},{"issue":"17","key":"10.1016\/j.ucl.2026.03.006_bib7","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Gu\u00e9rin for transitional-cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.006_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.006_bib9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0302-2838(03)00140-4","article-title":"Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study","volume":"43","author":"Kaasinen","year":"2003","journal-title":"Eur Urol"},{"issue":"suppl 1","key":"10.1016\/j.ucl.2026.03.006_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000475201","article-title":"BCG in perspective: advances in the treatment of superficial bladder cancer","volume":"27","author":"Lamm","year":"1995","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ucl.2026.03.006_bib11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ucl.2026.03.006_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-5347(17)46972-2","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer","volume":"134","author":"Lamm","year":"1985","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.006_bib13","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.03.006_bib14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2407-13-332","article-title":"Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparitive studies","volume":"13","author":"Zhu","year":"2013","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.006_bib15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.006_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.006_bib17","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.03.006_bib18","author":"Swanson"},{"key":"10.1016\/j.ucl.2026.03.006_bib19","author":"Merck"},{"key":"10.1016\/j.ucl.2026.03.006_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.urology.2023.02.044","article-title":"Variation in statewide intravesical treatment rates for non-muscle invasive bladder cancer during the bacillus calmette-guerin drug shortage","volume":"177","author":"Chun","year":"2023","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.006_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence rate and cost consequence of the shortage of bacillus Calmette-Gu\u00e9rin connaught strain for bladder cancer patients","volume":"7","author":"Ourfali","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.006_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.006_bib24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"issue":"19","key":"10.1016\/j.ucl.2026.03.006_bib25","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ucl.2026.03.006_bib26","series-title":"UpToDate","article-title":"Infectious complications of intravesical BCG immunotherapy","author":"O\u2019Donnell","year":"2024"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.006_bib27","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.006_bib28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.006_bib29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.006_bib30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat Rev Urol"},{"issue":"11","key":"10.1016\/j.ucl.2026.03.006_bib31","doi-asserted-by":"crossref","first-page":"490.e13","DOI":"10.1016\/j.urolonc.2022.05.016","article-title":"Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer","volume":"40","author":"Ferro","year":"2022","journal-title":"Urol Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.006_bib33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2002","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.006_bib34","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2005","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.ucl.2026.03.006_bib35","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1111\/ans.70281","article-title":"BCG intolerance in Nonmuscle invasive bladder Cancer-A systematic review","volume":"95","author":"Oh","year":"2025","journal-title":"ANZ J Surg"},{"issue":"suppl 1","key":"10.1016\/j.ucl.2026.03.006_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000052380","article-title":"Modified induction course: a solution to side-effects?","volume":"37","author":"Bassi","year":"2000","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.006_bib37","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1464-410X.2005.05817.x","article-title":"Intravesical bacillus Calmette-Gu\u00e8rin therapy: experience with a reduced dwell-time in patients with pronounced side-effects","volume":"96","author":"Andius","year":"2005","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.006_bib38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamaoncol.2023.6804","article-title":"Response to 2 induction courses of bacillus calmette-gu\u00e8rin therapy among patients with high-risk non-muscle-invasive bladder cancer: 5-year Follow-Up of a phase 2 clinical trial","volume":"10","author":"Katims","year":"2024","journal-title":"JAMA Oncol"},{"issue":"7\u20138","key":"10.1016\/j.ucl.2026.03.006_bib39","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0264-410X(98)00277-1","article-title":"A historical and molecular phylogeny of BCG strains","volume":"17","author":"Behr","year":"1999","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.006_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/iju.13538","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences as the basis for immunotherapies against bladder cancer","volume":"25","author":"Miyazaki","year":"2018","journal-title":"Int J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.006_bib41","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.juro.2012.09.049","article-title":"Connaught and Russian strains showed the highest direct antitumor effects of different Bacillus Calmette-Gu\u00e9rin substrains","volume":"189","author":"Secanella-Fandos","year":"2013","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.006_bib42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of bacillus Calmette-Gu\u00e9rin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.006_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020245","article-title":"Carcinoma In Situ (CIS): is there a difference in efficacy between various BCG strains? A comprehensive review of the literature","volume":"16","author":"Llano","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.006_bib44","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus calmette-gu\u00e9rin immunotherapy: are we there yet? A systematic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.006_bib45","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/JU.0000000000000355","article-title":"Evaluation of the fluorescence in situ hybridization Test to predict recurrence and\/or progression of disease after bacillus Calmette-Gu\u00e9rin for primary high grade nonmuscle invasive bladder cancer: results from a prospective multicenter trial","volume":"202","author":"Lotan","year":"2019","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.006_bib46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.urolonc.2013.10.012","article-title":"The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure","volume":"32","author":"Lima","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2026.03.006_bib47","article-title":"Immunological hallmarks for clinical response to BCG in bladder cancer","volume":"11","author":"Lim","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.006_bib48","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2022.09.008","article-title":"Elevated T-cell exhaustion and urinary tumor DNA levels are associated with bacillus calmette-gu\u00e9rin failure in patients with non-muscle-invasive bladder cancer","volume":"82","author":"Strandgaard","year":"2022","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.006_bib49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.urolonc.2018.05.014","article-title":"Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis","volume":"36","author":"Vartolomei","year":"2018","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.006_bib50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus calmette-gu\u00e9rin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"issue":"697","key":"10.1016\/j.ucl.2026.03.006_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn4118","article-title":"Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu\u00e9rin","volume":"15","author":"de Jong","year":"2023","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.006_bib53","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.euf.2023.06.006","article-title":"Background and update for ECOG-ACRIN EA8212: a randomized phase 3 trial of intravesical bacillus Calmette-Gu\u00e9rin (BCG) versus intravesical docetaxel and gemcitabine treatment in BCG-na\u00efve high-grade non-muscle-invasive bladder cancer (BRIDGE)","volume":"9","author":"Kates","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"23","key":"10.1016\/j.ucl.2026.03.006_bib54","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-Term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.006_bib55","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2026.03.006_bib56","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1007\/s00345-020-03329-2","article-title":"PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment","volume":"39","author":"Roumigui\u00e9","year":"2021","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.006_bib57","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.006_bib58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00345-024-05392-5","article-title":"PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG","volume":"43","author":"de Jong","year":"2025","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.006_bib59","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/JU.0000000000004541","article-title":"Artificial intelligence biomarkers predict poor efficacy of bacillus Calmette-Gu\u00e9rin rechallenge in previously bacillus calmette-gu\u00e9rin-treated nonmuscle-invasive bladder cancer","volume":"214","author":"Lotan","year":"2025","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.006_bib60","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.euo.2025.04.006","volume":"8","author":"Packiam","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.006_bib61","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.03.006_bib62","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1038\/s41598-017-03421-5","article-title":"Systematic review and cumulative analysis of the combination of Mitomycin C plus bacillus Calmette-Gu\u00e9rin (BCG) for non-muscle-invasive bladder cancer","volume":"7","author":"Deng","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.006_bib63","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","article-title":"Bacillus Calmette-Gu\u00e9rin with or without interferon \u03b1-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.006_bib64","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin with interferon-alpha versus intravesical bacillus Calmette-Gu\u00e9rin for treating non-muscle-invasive bladder cancer","volume":"3","author":"Shepherd","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.006_bib65","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ucl.2026.03.006_bib66","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2025.43.16_suppl.4517","article-title":"Sasanlimab in combination with bacillus Calmette-Gu\u00e9rin (BCG) in BCG-naive, high-risk non\u2013muscle-invasive bladder cancer (NMIBC): event-free survival (EFS) subgroup analyses based on disease stage from the CREST study","volume":"43","author":"Powles","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10516","key":"10.1016\/j.ucl.2026.03.006_bib67","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.006_bib68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.006_bib69","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2018.09.028","article-title":"Prognostic implication of the United States food and drug administration-defined BCG-unresponsive disease","volume":"75","author":"Li","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.006_bib70","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-Unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"issue":"20","key":"10.1016\/j.ucl.2026.03.006_bib71","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1158\/1078-0432.CCR-25-1231","article-title":"FDA approval summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-unresponsive carcinoma in situ","volume":"31","author":"Heiss","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ucl.2026.03.006_bib72","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.006_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.02.010","volume":"22","author":"Montgomery","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.006_bib74","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euo.2023.01.013","article-title":"A phase 1b\/2 Study of atezolizumab with or without Bacille Calmette-Gu\u00e9rin in patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"Inman","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.006_bib75","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: the hoosier cancer research network GU16-243 ADAPT-BLADDER Study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.03.006_bib76","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS579","article-title":"A phase II trial of intravesical chemoimmunotherapy with gemcitabine and bacillus calmette-Gu\u00e9rin (BCG) for patients with BCG-exposed, high-grade, non-muscle\u2013invasive bladder cancer","volume":"41","author":"Gaffney","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:56:52Z","timestamp":1782507412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0094014326000327"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.006","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bacillus Calmette-Gu\u00e9rin Therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}